FDA Panels Favor Advair, Symbicort Over Single-Entity LABA Products For Asthma
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency must consider whether to change labeling, institute REMS or withdraw the indications for Serevent and Foradil, OND's Jenkins says.